Nicole Clare Gavin

Nicole Clare Gavin

Auto-generated profile, based on publicly available information

Nicole Clare Gavin

Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2017 in Trials
Verified
Journal Article
Open access
PDF file
RCRaymond J. Chan
Raymond J. Chan
SNSarah Northfield
Sarah Northfield
ELEmily Larsen
Emily Larsen
GMGabor Mihala
Gabor Mihala
AUAmanda Ullman
Amanda Ullman
CRClaire M. Rickard
Claire M. Rickard
Peripherally inserted central catheters (PICCs) are commonly used for delivering intravenous therapy. PICC failure is unacceptably high (up to 40%) due to mechanical, infectious and thrombotic complications. Poor securement potentiates all complication types. This randomised controlled trial (RCT) aimed to examine the feasibility of a large RCT of four dressing and securement methods to prevent PICC failure. This single-centre pilot RCT included 124 admitted medical/surgical/cancer patients aged ≥ 16 years with a PICC. Interventions were: (i) standard polyurethane dressing and sutureless securement device (SPU + SSD, control); (ii) polyurethane with absorbent lattice pad dressing (PAL + Tape); (iii) combination securement-dressing (CSD); and (iv) tissue adhesive (TA + SPU). All groups except TA + SPU had a chlorhexidine-gluconate (CHG) impregnated disc. Feasibility outcomes were recruitment and safety/acceptability of the interventions. The primary outcome was PICC failure, a composite of PICC removal for local infection, catheter-associated bloodstream infection, dislodgement, occlusion, and/or catheter fracture. Secondary outcomes included individual complications, dressing failure and dwell time, PICC dwell time, skin complications/phlebitis indicators, product costs, and patient and staff satisfaction. Qualitative feedback was also collected. PICC failure incidence was: PAL + CHG + Tape (1/5; 20%; 17.4/1000 days), SPU + SSD + CHG (control) (4/39; 10%; 9.0/1000 days), TA + SPU (3/35; 9%; 9.6/1000 days), and CSD + CHG (3/42; 7%; 9.4/1000 days). Recruitment to PAL + CHG + Tape was ceased after five participants due to concerns of PICC dislodgement when removing the dressing. CSD + CHG, TA + SPU (TA applied only at PICC insertion time), and control treatments were acceptable to patients and health professionals. A large RCT of CSD + CHG and TA + SPU (but not PAL + CHG + Tape) versus standard care is feasible. Australian and New Zealand Clinical Trials Registry, ACTRN12616000027415 . Registered on 15 January 2016.

4 September 2018 in Australian Health Review
Verified
Journal Article
Closed access
PDF file
HTHaitham Tuffaha
Haitham Tuffaha
NMNicole Marsh
Nicole Marsh
Joshua ByrnesJoshua Byrnes
Joshua Byrnes
NGNicole Gavin
Nicole Gavin
JWJoan Webster
Joan Webster
CRClaire M. Rickard
Claire M. Rickard
Objective: The aim of this study was to quantify the utilisation of vascular access devices in Queensland public hospitals and their associated cost. Methods: Devices were broadly classified into peripheral intravenous catheters, central venous catheters and arterial lines. The number of catheters used was obtained from a central procurement department at Queensland Health and validated using Medicare Benefits Schedule (MBS) claims and/or hospital data from the Australian Institute of Health and Welfare for the same period. Resources consumed included equipment and staff time required to insert and remove catheters. Equipment costs were valued using negotiated hospital prices, and staff time was valued at the fixed industrial award wages in Australia or relevant MBS fees. Device maintenance costs (e.g. dressings) and costs of treating complications were excluded. Results: Approximately 2.75 million vascular access devices were used in public hospitals in Queensland in 2016, at a total cost of A$59.14 million. This comprised a total equipment cost of around A$10.17 million and a total labour cost of A$48.85 million Conclusion: Vascular access is an important component of healthcare expenditure. The present study is the first to characterise and cost vascular access devices in Queensland. Further research is needed on the costs of maintaining device function and of treating complications associated with vascular access. What is known about the topic?: The cost of vascular access in Australia has previously been estimated from modelling, using various assumptions, or based on device utilisation in other countries. What does this paper add?: For the first time, device utilisation for vascular access in Queensland has been quantified and costed. Results were obtained from reliable sources and validated against other databases. What are the implications for practitioners?: Practitioners and managers may now provide accurate estimates about the cost of catheter failure, a potentially preventable problem that affects up to 50% of all catheters placed. Attaching costs to such failure may also stimulate research into how to reduce the problem.

1 February 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
NGNicole C Gavin
Nicole C Gavin
JWJoan Webster
Joan Webster
RCRaymond J. Chan
Raymond J. Chan
CRClaire M Rickard
Claire M Rickard

26 August 2022 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
MNMidori Nakagaki
Midori Nakagaki
GKGlen A. Kennedy
Glen A. Kennedy
NGNicole C. Gavin
Nicole C. Gavin
ACAlexandra Clavarino
Alexandra Clavarino
Karen WhitfieldKaren Whitfield
Karen Whitfield
Purpose: Oral mucositis is a common complication during haematopoietic stem cell transplantation (HSCT). This study aimed to assess the incidence of severe mucositis in patients undergoing different HSCT regimens. Methods: This single-centre retrospective study reviewed daily oral assessment for 467 consecutive patients who underwent different transplant regimens for matched unrelated or related allogeneic HSCT with post-transplant methotrexate, haploidentical or mismatched HSCT with post-transplant cyclophosphamide (PTCy), or autologous HSCT. Oral care and cryotherapy with melphalan were used. Patient demographic data, oral mucositis WHO grade, use of total parenteral nutrition (TPN) and patient-controlled analgesia (PCA) were collected. Results: Grade 3–4 oral mucositis was common in myeloablative total body irradiation (TBI)-based regimens cyclophosphamide/ TBI (CyTBI) (71%) and fludarabine/ TBI (FluTBI) with PTCy (46%), as well as reduced-intensity fludarabine/melphalan (FluMel) (43%) and carmustine/etoposide/cytarabine/melphalan (BEAM) autologous HSCT (41%). In contrast, grade 3–4 oral mucositis was less common in reduced-intensity haploidentical regimen melphalan/fludarabine/TBI with PTCy (19%), all non-myeloablative regimens (0–9%) and high-dose melphalan autologous HSCT (26%). TPN and PCA use were correlated to oral mucositis severity. Conclusions: Severe oral mucositis was associated with myeloablative TBI, methotrexate and melphalan in combination with methotrexate and in BEAM. Use of PTCy was preferable over methotrexate to prevent oral mucositis.

31 July 2019 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
ELEmily N. Larsen
Emily N. Larsen
NGNicole Gavin
Nicole Gavin
NMNicole Marsh
Nicole Marsh
CRClaire M. Rickard
Claire M. Rickard
NRNaomi Runnegar
Naomi Runnegar
JWJoan Webster
Joan Webster
Objective: To establish the reliability of the application of National Health and Safety Network (NHSN) central-line–associated bloodstream infection (CLABSI) criteria within established reporting systems internationally.Design: Diagnostic-test accuracy systematic review.Methods: We conducted a search of Medline, SCOPUS, the Cochrane Library, CINAHL (EbscoHost), and PubMed (NCBI). Cohort studies were eligible for inclusion if they compared publicly reported CLABSI rates and were conducted by independent and expertly trained reviewers using NHSN/Centers for Disease Control (or equivalent) criteria. Two independent reviewers screened, extracted data, and assessed risk of bias using the QUADAS 2 tool. Sensitivity, specificity, negative and positive predictive values were analyzed.Results: A systematic search identified 1,259 publications; 9 studies were eligible for inclusion (n = 7,160 central lines). Publicly reported CLABSI rates were more likely to be underestimated (7 studies) than overestimated (2 studies). Specificity ranged from 0.70 (95% confidence interval [CI], 0.58–0.81) to 0.99 (95% CI, 0.99–1.00) and sensitivity ranged from 0.42 (95% CI, 0.15–0.72) to 0.88 (95% CI, 0.77–0.95). Four studies, which included a consecutive series of patients (whole cohort), reported CLABSI incidence between 9.8% and 20.9%, and absolute CLABSI rates were underestimated by 3.3%–4.4%. The risk of bias was low to moderate in most included studies.Conclusions: Our findings suggest consistent underestimation of true CLABSI incidence within publicly reported rates, weakening the validity and reliability of surveillance measures. Auditing, education, and adequate resource allocation is necessary to ensure that surveillance data are accurate and suitable for benchmarking and quality improvement measures over time.Registration: Prospectively registered with International prospective register of systematic reviews (PROSPERO ID CRD42015021989; June 7, 2015). https://www.crd.york.ac.uk/PROSPERO/display_record.php?ID%3dCRD42015021989

1 March 2010 in British Journal of Nursing
Verified
Journal Article
Closed access
JWJoan Webster
Joan Webster
NGNicole Gavin
Nicole Gavin
CNCatherine Nicholas
Catherine Nicholas
KCKerrie Coleman
Kerrie Coleman
GGGlenn Gardner
Glenn Gardner
Aim: To assess the validity of the Waterlow screening tool in a cohort of internal medicine patients and to identify factors contributing to pressure injury. Method:A longitudinal cohort study design was used. A total of 274 patients (mean age 65.3 years) admitted through the emergency department or outpatient clinics of a tertiary hospital in Brisbane, Australia, and expected to remain in hospital for at least 3 days were screened on admission using the Waterlow screening tool. Their pressure ulcer status was monitored and recorded every second day. The main outcome measure was pressure ulcer incidence. Results: Fifteen participants (5.5%) had an existing pressure ulcer and a further 12 (4.4%) developed a pressure ulcer during their hospital stay. Sensitivity of the Waterlow scale was 0.67 (95% confidence interval [CI]: 0.35–0.88), specificity was 0.79 (95% CI: 0.73–0.85), positive predictive value was 0.13 (95% CI: 0.07–0.24) and negative predictive value was 0.98 (95% CI: 0.94–0.99). Conclusion: This study provides further evidence of the poor predictive validity of the Waterlow scale. A suitably powered, randomized controlled trial is urgently needed to provide definitive evidence about the usefulness of the Waterlow scale compared with other screening tools and with clinical judgment.